Somatic and psychological effects of low-dose aromatase inhibition in men with obesity-related hypogonadotropic hypotestosteronemia
Sandra Loves, Jos de Jong, Adriaan van Sorge, Darryl Telting, Cees Tack, Ad Hermus, Klaas Westerterp, Hans de Boer (2013) Somatic and psychological effects of low-dose aromatase inhibition in men with obesity-related hypogonadotropic hypotestosteronemia Eur J Endocrinol (IF: 5.2) 169(5) 705-14Abstract
Reduced testosterone levels are frequently observed in obese men. Increased aromatase activity may be an etiological factor.In this study, we evaluate the clinical effects of aromatase inhibition in obesity-related hypogonadotropic hypotestosteronemia (OrHH).Double-blind, placebo-controlled, 6-month trial in 42 obese men with a BMI >35 kg/m(2), and a serum total testosterone <10 nmol/l. All patients started on one tablet of 2.5 mg/week, with subsequent dose escalation every month until a serum total testosterone of 20 nmol/l was reached.Psychological function, body composition, exercise capacity, and glucose, lipid, and bone metabolism.Thirty-nine patients completed the study according to protocol. Letrozole decreased serum estradiol from 119.1±10.1 to 59.2±6.1 pmol/l (P<0.001), and increased serum LH from 3.3±0.3 to 8.8±0.9 U/l (P<0.0001) and serum total testosterone from 8.6±0.7 to 21.5±1.3 nmol/l (P<0.0001). Significant effects on the predefined endpoints were not observed.Despite a marked rise in serum testosterone, low-dose aromatase inhibition had no somatic or psychological effects in men with OrHH.
Links
http://www.ncbi.nlm.nih.gov/pubmed/23949882http://dx.doi.org/10.1530/EJE-13-0190
Similar articles
Tools
